For over a decade commercial companies have offered pharmacogenetic testing to psychiatric providers with the promise that the results will assist medication choice or dosing. While the concept of personalized medicine has great appeal and represents the forefront of research in many areas, the applicability and value in psychiatric practice remains a subject of intense debate. As will be discussed below, the problems with testing lie not only in what is reported, but also the difficulties encountered by clinicians when interpreting the significance of assay findings and implementing them to benefit patient care.

Fundamental to this debate rests on the fact that there is large variation in what various guidelines and commercial reports recommend to clinicians, even for basic information such as the significance of interactions between prescribed drugs and genetic variants that influence pharmacokinetics (i.e. drug clearance). A 2022 commentary entitled Clinical Use of Pharmacogenomics in Psychiatry: The Future Has Not Yet Arrived in the prestigious journal European Neuropsychopharmacology lamented: “The challenges of the translation of candidate genes with relevance to pharmacokinetic mechanisms (e.g., CYP2C19, CYP2D6, CYP2C9) into clinical practice is also demonstrated by the fact that various guidelines on the use of pharmacogenomic information for specific drug-gene pairs (including 33 relevant for Psychiatry) show large variation, demonstrate in part contradictions in recommendations even on the same drugs and lack wide adoption by clinical services.”

This lack of agreement among commercial tests has been noted for over half a decade, with reviews and expert consensus papers in 2018 concluding that the data did not establish the value of such testing.1,4

Recently published papers do recognize the possible benefits in identifying genetic variations associated with slower drug clearance (leading to higher rates of adverse effects for a given dose) or more rapid drug clearance (leading to lack of effective drug levels), but clinicians may not fully appreciate the caveats in using this information. Commercial tests report information on 6 or more cytochrome P450 enzymes (CYP 450), yet a comprehensive 2021 review focusing on commonly used antipsychotics and antidepressants noted that evidence, guidelines, and product labels supported testing for only 2 of these genes (CYP2D6, CYP2C19).1 Moreover, a 2019 study of patients with major depression found genetic testing did not significantly improve the average extent of symptom reduction, but did increase the proportion rated as responders.4 The conclusion from this literature is that testing can alert clinicians to situations where drug levels might be lower than expected for a given dose and thereby pursue higher dosages in those patients who clear medications more quickly, assuming that the medication is metabolized by one of those two CYP genes; however, this will not influence the maximal ability of the drug to be effective once therapeutic drug levels are reached.

While one would correctly conclude that a similar principle applies to antipsychotics, namely that certain genetic variations present a risk for drug levels that are too high or too low, the situation may be a bit more complex for several reasons:

1) Clinicians may focus so heavily on the genetic testing results that they overlook potential interactions from other co-prescribed medications that can slow or accelerate antipsychotic clearance. Patients living with schizophrenia are often on complex medication regimens;

2) Individuals may have variations in more than one CYP enzyme making it difficult to determine the net effect on drug clearance;

3) Inherent to many chronic disorders, especially serious mental illnesses such as schizophrenia, is poor adherence with oral medication therapy. Genetic testing will not help a clinician decide why a patient might be an inadequate responder to seemingly effective antipsychotic dosages – only plasma drug levels will provide that answer;

4) Certain nutritional supplements and cigarette smoking (e.g. actual burning of the leaf, not vaping) may expose a patient to chemicals that alter antipsychotic clearance; and

5) There is no genetic test or imaging study available that predicts response to antipsychotics in general, or to specific agents.

continues on page 4
SCHIZOPHRENIA SURVIVORS

Liz Grace (Pen Name)
Conquering Deafness and Schizophrenia

Liz Grace describes her childhood as happy, up until she was 10 years old, when her mother died from breast cancer. Afterwards, she remembers life as lonely and difficult. For the first few years after her mother’s diagnosis, her maternal grandparents moved closer to Liz’s family and were always loving, supportive, and emotionally close to Liz throughout her whole life. However, she was not close to her three siblings after her mother’s death.

Liz remembers doing satisfactory work in elementary and high school, but it was not her best. She was smart, and though she often didn’t do her homework, she sometimes corrected her teachers’ academic mistakes in math classes.

Liz decided to add another year of high school, often called a “victory lap,” because she had failed three of her classes during her fourth year due to lack of motivation, which was caused by her declining mental health.

Staying in high school for an extra year was difficult because all her friends had graduated and moved on to college. During that year, Liz sank into a deep depression. She hated herself and was unhappy. Her memory was failing her, and she struggled with basic memorization in classes.

At times, while in high school, she experienced voices in her head, laughing at her like a laugh track on a TV show. Fortunately, these voices disappeared for many years and would not bother her again until adulthood.

In October 2005, during her fifth year of high school at age 17, Liz experienced her first suicidal thoughts. Her grades dropped, and she chose to see a counselor without telling anyone.

From age 16, Liz also struggled with rapid hearing loss due to a genetic condition. From 2016 until 2022 she worked about various community activities.

Liz was excited to graduate from high school and finally move on to enjoy the independence of being an adult. After high school, she enrolled in college in Toronto where she lived in a dormitory on campus. Finally, she realized she needed the antidepressant, and in treatment, she lived in nearly full remission. She excelled in college without any hospitalizations for the next eight years.

Today, Liz has achieved recovery on the antipsychotic cariprazine, bupropion, and the mood stabilizer lithium. She is surviving and thriving, working full-time while being the primary caregiver for her grandmother. She also has her own small business and participates in various community activities.
When the Laitmans’ son Daniel presented with symptoms of psychosis in 2006, they never dreamed that he would achieve a meaningful recovery, let alone that so much good would come out of his struggle with treatment-resistant schizophrenia.

Dr. Laitman remembers his first rotation on a psychiatric ward in the late 70’s, where he described the care as “terrible.” “The older antipsychotic medications (first generation) were in use, and patients often had unbearable side effects, while getting little benefit. Upon his graduation from medical school at Washington University in Saint Louis in 1983, Dr. Laitman decided to become an internist, and then eventually, to specialize in nephrology.

Dr. Laitman married Dr. Ann Mandel in 1986. Over the next decade, they had a daughter, a son and identical twin girls.

In early elementary school, Dr. Laitman’s son Daniel seemed to be struggling. He suffered from anxiety, and occasionally had a “meltdown.” He was sensitive to loud noises. At age eight, following an allergic reaction, he took steroids, which made him psychotic. Although the medication induced psychosis disappeared quickly, Dr. Laitman looks back on it as a warning sign.

From second grade onward, Daniel was diagnosed with ADD, began therapy, and took medication. But Dr. Laitman remembers Daniel as a happy kid. He had friends and looked forward to summer camp.

Unfortunately, Daniel’s struggles soon took a turn for the worse at age 15, during summer camp, when he began to hear voices. Common hallucinations took over his thinking, threatening to steal his soul. He was commanded to hold his arm in uncomfortable positions and not put his head down on a pillow.

As Daniel grew worse, the Laitmans began to read widely about schizophrenia and treatment, and look for advocacy organizations. Dr. Laitman remembers being told that he needed to lower his expectations and that Daniel would have a “different life.” He remembers crying over his son’s impossible situation, although he almost never cried.

Despite the hopelessness he encountered, the Laitmans resolved to never give up on Daniel. After several months, it became clear that Daniel was resistant to schizophrenia medications. Looking for help, Dr. Laitman contacted Dr. Deborah Levy, who was the head of Harvard’s McLean Psychology Research Lab. At that time, an effective treatment for Daniel was becoming more urgent, as he was becoming suicidal.

Following extensive research and many conversations with experts, Dr. Laitman discovered the underutilized medication clozapine, which is the only medication for treatment-resistant schizophrenia. He was also warned that the medication should only be used for the most severe cases. With careful monitoring, Daniel began clozapine in March of 2008 at age 17. Within weeks, it was apparent that clozapine was radically different than any other medication Daniel had tried. After a few months, his symptoms were soon in remission.

However, shortly after Daniel started clozapine, he developed aspiration pneumonia and severe constipation. These side effects were treated while he continued to take clozapine. In order to remain on clozapine, Daniel also needed weekly bloodwork, which was a challenge to coordinate with their pharmacy.

As the side effects of clozapine abated, Daniel was able to resume a normal life. Because of this, the Laitmans realized the great need to make clozapine available to treatment-resistant adolescents, enabling many of them to achieve full symptoms remission. They also knew that the side effects needed to be managed carefully.

Dr. Laitman was still practicing nephrology, but he realized that becoming certified to prescribe clozapine (with the Risk Evaluation and Management Strategies, or REMS system) was within his reach. He began collecting Daniel’s blood by himself at home and managing Daniel’s medications.

Today, Dr. Laitman does not consider himself a psychiatrist but a “psychiatric internist.” The COVID pandemic led to a movement of doctors using telehealth. Today, thanks to telehealth, Dr. Laitman sees over two hundred patients in thirty states whom he monitors on clozapine.

Many travel to New York to see him in person once a year.

Thanks to Dr. Laitman and like-minded psychiatrists that work for the office of mental health, the use of clozapine has increased in their facilities from 2.8% to 20%. Today, he also travels around the country giving presentations about the use of clozapine and dispelling myths that clozapine should not be used or is dangerous.

For decades, clozapine has been used as a medication of last resort. Sometimes, even today, patients who fail several antipsychotic trials suffer for years before clozapine is even considered. Dr. Laitman’s mission is to introduce clozapine earlier on the patient’s journey to recovery, to offer the best outcome. Over the years, he has seen many success stories. He hopes that through his professional work, and also through the advocacy work of Team Daniel, more lives will be radically changed as Daniel’s has been.

In 2017, Dr. Laitman published a book together with his wife and Daniel titled “Meaningful Recovery from Schizophrenia with Clozapine.” In his book, he describes how to minimize and treat clozapine side effects in great detail, including how to treat rare side effects. During this time, Dr. Laitman contacted the organization which had told him to lower his expectations with a message: “Don’t grieve your children. Make them better!”

Over the last fifteen years, Dr. Laitman has proposed a change in the position of clozapine from the drug of last resort to a drug that should be considered early in the first episode of psychosis in those not showing an optimal response with the first antipsychotic used. Clozapine can take the care of psychosis from good enough to optimal. Dr Laitman believes that everyone who is fully engaged and has not shown an optimal response should be given this opportunity.
issues with Pharmacogenetic Testing to Optimize Antipsychotic Therapy
(continued from page 1)

This confluence of issues may explain why no study has found that the use of commercial genetic testing significantly improves outcomes in patients living with schizophrenia, but it does explain why there has been a resurgence of interest in directly measuring antipsychotic levels to accurately quantify how the independent effects of nonadherence, genetic variants, other medications, supplements and smoking sum to influence how a given medication is cleared and whether it is being taken as prescribed.15,16

Clozapine is an important example of the limitations imposed by use of genetic testing. Clozapine is the only medication effective for individuals with treatment resistant schizophrenia, but it has complex metabolism, with one study showing the average contributions of CYPs 1A2, 2C19, 3A4, 2C9, and 2D6 were 30%, 24%, 22%, 12%, and 6%, respectively.15 CYP1A2 is very sensitive to the effects of cigarette smoking, and those who smoke typically require dosages 50% higher than nonsmokers to achieve the same clozapine level.11 The magnitude of this effect will only be seen if the clinician orders a clozapine level. Importantly, given that population variations exist for many of these CYPs, and that a significant proportion of patients living with schizophrenia do smoke, recent recommendations focus on tailoring early clozapine dosing to the patient’s ancestry and smoking behavior to avoid unnecessarily high drug levels during the early phase of treatment, and then checking levels to determine the net effects of all of these factors for that patient. To add another layer of complexity to this situation, clozapine has an active metabolite, norclozapine, and 83% of its clearance does not rely on a CYP but instead on a renal (kidney) drug transporter called P-glycoprotein (PGP).15,16 Not surprisingly, both the expression of and the function of PGP exhibit population variations in the same manner as do CYPs.16 and this variability represents an aspect of norclozapine clearance that is not captured by many commercial genetic assays.15,16

The problems with pharmacogenetic testing (PGx) in psychiatry can be summed up nicely by a 2023 review which concluded: “Clinicians varied greatly in their application of test results for clinical decision making regarding medications, many were uncertain how much to rely on the results, and differed in perceptions about which patients would benefit from PGx.” There is hope that, in the future, genetic testing will significantly improve the accuracy of antipsychotic treatment and patient outcomes. That future, lamentably, has not yet arrived.

Conflicts of Interest:
Dr. Meyer reports receiving research or advising fees in the past 24 months from: AbbVie, Alkermes, BioXcel, ITIC, Karuna, Neurocrine, Noven, Otsuka-USA, Sunovion Pharma (formerly Sunovion) and Teva.

References:
10. Olesen OV, Linnet K. Contributions of CYPs 1A2, 2C19, 3A4, 2C9, and 2D6 were 30%, 24%, 22%, 12%, and 6%, respectively.15 CYP1A2 is very sensitive to the effects of cigarette smoking, and those who smoke typically require dosages 50% higher than nonsmokers to achieve the same clozapine level.11 The magnitude of this effect will only be seen if the clinician orders a clozapine level. Importantly, given that population variations exist for many of these CYPs, and that a significant proportion of patients living with schizophrenia do smoke, recent recommendations focus on tailoring early clozapine dosing to the patient’s ancestry and smoking behavior to avoid unnecessarily high drug levels during the early phase of treatment, and then checking levels to determine the net effects of all of these factors for that patient. To add another layer of complexity to this situation, clozapine has an active metabolite, norclozapine, and 83% of its clearance does not rely on a CYP but instead on a renal (kidney) drug transporter called P-glycoprotein (PGP). Not surprisingly, both the expression of and the function of PGP exhibit population variations in the same manner as do CYPs, and this variability represents an aspect of norclozapine clearance that is not captured by many commercial genetic assays.

Please consider making a donation to the CURESZ Foundation online at CURESZ.org
Your contribution will help provide education and referrals to persons with schizophrenia, their families, and those who work with the seriously mentally ill. CURESZ informs the general public to better understand this serious brain disorder, and to provide scientific advances showing that there is hope for recovery, and a return to a fulfilling and normal life. The CURESZ Foundation is a 501(c)(3) nonprofit organization. All contributions are tax deductible.

“We are committed to helping individuals to cope with and recover from schizophrenia.”

You can now also support the CURESZ Foundation by signing up with Kroger Community Rewards.